Universal Pneumococcal Vaccine

Streptococcus pneumoniae infections cause diseases with considerable morbidity and mortality. Polysaccharide or conjugated vaccines induce serotype-specific antibodies, limiting clinical effectiveness. Emergence of new bacterial serotypes necessitate a new vaccination approach. Virometix is developing an epitope-based, serotype-independent, pneumococcal vaccine based on novel immunodominant, highly conserved antigens. The vaccine candidates are being developed in collaboration with the Children’s Hospital in Athens.